SMAD公司
脱氮酶
发病机制
纤维化
肾
泛素
医学
病态的
转化生长因子
内科学
内分泌学
癌症研究
药理学
化学
基因
生物化学
作者
Guang Liang,Ying Zhao,Xi Chen,Yimin Lin,Zhongding Li,Xian Su,Bozhi Ye,Yanghao Chen,Shijie Fan,Xu Wang
出处
期刊:Research Square - Research Square
日期:2022-08-19
标识
DOI:10.21203/rs.3.rs-1884837/v1
摘要
Abstract Renal fibrosis is a crucial pathological feature of hypertensive renal disease (HRD). In-depth analysis of the pathogenesis of fibrosis is of great significance for the development of new drugs for the treatment of HRD. USP25 is a deubiquitinase that can regulate the progression of many diseases, but its function in the kidney remains unclear. We found that USP25 was significantly increased in human and mouse HRD kidney tissues. In the HRD model induced by Ang II, USP25 −/− mice showed significant aggravation of renal dysfunction and fibrosis compared with the control mice. Consistently, AAV9-mediated overexpression of USP25 significantly improved renal dysfunction and fibrosis. Mechanistically, USP25 inhibited the TGF-β pathway by reducing SMAD4 k63-linked polyubiquitination, thereby suppressing SMAD2 nuclear translocation. In conclusion, this study demonstrates for the first time that the deubiquitinase USP25 plays an important regulatory role in HRD.
科研通智能强力驱动
Strongly Powered by AbleSci AI